Quanterix’s rigorously developed assay (Janssen Assay (p217+ tau)) provides unprecedented accuracy and sensitivity, empowering researchers to discover vital insights into Alzheimer’s disease pathology.
Researchers can rely on the Janssen p217+ tau assay, which has been validated through multiple published clinical studies. This validation ensures consistent and reliable measurements of p-Tau 217 across diverse sample types.
Customizing the design of a testing plan to meet specific research requirements and utilizing the Accelerator Lab’s high throughput capabilities for large-scale Alzheimer’s and drug development research enhances the generation of insightful results.
Elevating research with Quanterix’s accelerator lab services
Quanterix’s p217+ tau assay, combined with the expertise of Quanterix’s Accelerator Lab, enables researchers to extend the boundaries of current Alzheimer’s research.
Working with Quanterix opens the door to groundbreaking discoveries, empowering researchers to join the fight against neurodegenerative diseases with confidence and precision. This collaboration could redefine the face of Alzheimer’s research, helping to cement a promising future.
Pricing for p217+ tau assay
For further details on pricing regarding the p217+ tau assay, contact a member of the Quanterix team today.
Source: Quanterix
| Janssen p217+ tau | |
|---|---|
| Assay Platform | Quanterix Simoa® |
| Instrument | HD-X Analyzer |
| General Description | 3-step digital enzyme immunoassay |
| Automation | Fully automated |
| Assay Timing | 35-5-5 min |
| Capture Antibody | PT3 mouse monoclonal: epitope = aa 210-220, requiring p217, with enhanced binding with p212 |
| Detector Antibody | hT43: epitope = aa 7-20 |
| Calibrator Material | Synthetic peptide |
| Dynamic Range | 0.005-30.0 pg/mL |
| Calibrator Points # | 7 + blank |
| Calibrator Fitting | 1/y2 weighted 4PL |
| Signal Enzyme/Substrate | Streptavidin-b-galactosidase (SBG) |
| Substrate | Resorufin-β-D-galacto pyranoside |
| Sample Type | Human plasma (K2 EDTA) |
| Sample Volume | 172 μL for duplicate testing |
| Sample Dilution | 2x |
| Limit of Detection | 0.002 pg/mL1,2 |
| Functional Limit of Quantification | 0.037 pg/mL1,2 (accounts for 1:2 sample dilution) |
| Intra-Run Precision (%CV) | 7.1% (mean, plasma from 229 pts)3 |
| Inter-Run Precision (%CV) | 4.6% (plasma, 5 days)3 |
| Parallelism | Up to 6-fold dilution3 |
| Clinical Accuracy CI A+T+ | AUC 0.924 |
| Clinical accuracy CU Ab | AUC 0.863 |
1. Triana-Baltzer G, Moughadam S, Slemmon R, et al. Development and validation of a high-sensitivity assay for measuring p217+tau in plasma. Alzheimers Dement (Amst). 2021;13(1):e12204. Published 2021 May 27. doi:10.1002/dad2.12204
2. Triana-Baltzer G, Saadi Z, Moughadam S, et al. Janssen Simoa Plasma P217+Tau Assay As A Precision Prescreening Tool In Auτonomy Ph2 Anti-Tau Monoclonal Ab Trial In Early Alzheimer’s Disease. Abstract presented at: Clinical Trials Alzheimer’s Disease; November 29- December 2, 2022; San Francisco, CA
3. Doré V, Doecke JD, Saad ZS, et al. Plasma p217+tau versus NAV4694 amyloid and MK6240 tau PET across the Alzheimer‘s continuum. Alzheimers Dement (Amst). 2022;14(1):e12307. Published 2022 Apr 5. doi:10.1002/dad2.12307
4. Benedet AL, Pola I, Triana-Baltzer, et al. Plasma pTau217: single vs multiple phospho-site assays. Poster presented at: Poster presented at: Alzheimer‘s Association International Conference; July 16-20, 2023; Amsterdam, Netherlands
About Quanterix
From discovery to diagnostics, Quanterix’s ultrasensitive biomarker detection is fueling breakthroughs only made possible through its unparalleled sensitivity and flexibility. Quanterix’s Simoa® technology has delivered the gold standard for earlier biomarker detection in blood, serum or plasma, with the ability to quantify proteins that are far lower than the Limit of Quantification (LoQ) of conventional analog methods.
Its industry-leading precision instruments, digital immunoassay technology and CLIA-certified Accelerator laboratory have supported research that advances disease understanding and management in neurology, oncology, immunology, cardiology and infectious disease. Quanterix has been a trusted partner of the scientific community for nearly two decades, powering research published in more than 2,500 peer-reviewed journals.
Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.Net which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.
